ERBB2 and cancer: Moreover, molecular modeling studies using PyRx revealed that 4a, among all SOXs, was found to be the best inhibitor of distinct biomarkers associated with cancer progression, i.e., human CD-44, EGFR, AKR1D1, and HER-2.